149 related articles for article (PubMed ID: 12138343)
1. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin.
Lucia MB; Rutella S; Leone G; Larocca LM; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):369-78. PubMed ID: 12138343
[TBL] [Abstract][Full Text] [Related]
2. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
3. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
4. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy.
Núñez M; Saballs P; Valencia ME; Santos J; Ferrer E; Santos I; Berrocal A; Galindo MJ; Podzamczer D; Gonzlez-Lahoz J;
HIV Clin Trials; 2001; 2(5):429-37. PubMed ID: 11673818
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
Martin-Carbonero L; Barrios A; Saballs P; Sirera G; Santos J; Palacios R; Valencia ME; Alegre M; Podzamczer D; González-Lahoz J;
AIDS; 2004 Aug; 18(12):1737-40. PubMed ID: 15280789
[TBL] [Abstract][Full Text] [Related]
6. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Lucia MB; Anu R; Handley M; Gillet JP; Wu CP; De Donatis GM; Cauda R; Gottesman MM
Br J Cancer; 2011 Aug; 105(4):513-22. PubMed ID: 21829205
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
Bossi P; Legrand O; Faussat AM; Legrand M; Bricaire F; Marie JP; Agut H; Diquet B; Katlama C; Huraux JM; Calvez V
HIV Med; 2003 Jan; 4(1):67-71. PubMed ID: 12534962
[TBL] [Abstract][Full Text] [Related]
8. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
9. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
[TBL] [Abstract][Full Text] [Related]
10. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
Leitch H; Trudeau M; Routy JP
HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
[TBL] [Abstract][Full Text] [Related]
11. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
Loke WC; Spittle MF; Mitchell S; Kulasegaram R
Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
[TBL] [Abstract][Full Text] [Related]
12. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma.
Esdaile B; Davis M; Portsmouth S; Sarker D; Nelson M; Gazzard B; Bower M
AIDS; 2002 Nov; 16(17):2344-7. PubMed ID: 12441811
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
Mosam A; Shaik F; Uldrick TS; Esterhuizen T; Friedland GH; Scadden DT; Aboobaker J; Coovadia HM
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):150-7. PubMed ID: 22395672
[TBL] [Abstract][Full Text] [Related]
14. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin.
Hengge UR; Esser S; Rudel HP; Goos M
Eur J Cancer; 2001 May; 37(7):878-83. PubMed ID: 11313176
[TBL] [Abstract][Full Text] [Related]
15. Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma.
Carleo MA; Di Martino F; Del Giudice A; Gargiulo M; Parrella G; Rosario P; Sangiovanni V; Viglietti R; Esposito V; Chirianni A
In Vivo; 2015; 29(1):133-6. PubMed ID: 25600542
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.
Bourboulia D; Aldam D; Lagos D; Allen E; Williams I; Cornforth D; Copas A; Boshoff C
AIDS; 2004 Feb; 18(3):485-93. PubMed ID: 15090801
[TBL] [Abstract][Full Text] [Related]
17. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group.
Núñez M; Machuca A; Soriano V; Podzamczer D; González-Lahoz J
AIDS; 2000 May; 14(8):913-9. PubMed ID: 10853972
[TBL] [Abstract][Full Text] [Related]
18. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
19. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
20. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
